Clinical trajectories of patients with multiple sclerosis from onset and their relationship with serum neurofilament light chain levels.

ABSTRACT:

Background

Serum neurofilament light chain (sNfL) is a biomarker of neuroaxonal destruction that correlates with acute inflammation (AI) in multiple sclerosis (MS). However, in the treatment era, progression without AI is the main driver of long-term disability. sNfL may provide added value in detecting ongoing axonal damage and neurological worsening in patients without AI. We conducted a prospective three-year study on patients with a first MS relapse to evaluate the basal cut-off value predicting early increased disability unrelated to relapses.

Methods

sNfL levels and AI presence were measured every 6 months during the first year and the Expanded Disability Status Scale (EDSS) was monitored until the third year. Baseline cohorts were stratified by sNfL levels, using a cu

SUBMITTER: Quintanilla-Bordas C 

PROVIDER: S-EPMC11559265 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature